简介：Braintumorsincidenceinpediatricagehasbeenestimatedbetween1.3to5%witharelativeincidenceof1.4to11%duringthefirstyearoflife;theimprovementininstrumentaldeviceshasleadtoarelativeincreaseinprecociousdiag-nosis.Thechoicetostudybraintumorsofthefirstyearoflifeasaseparatetopicfrompediatricageonesdependsontheobservationthatthesele-sionshavepeculiarclinical,topographicandtis-sularcharacteristics.Thesurvivalrateofthesepatientsisverypoorifcomparedwiththatfound

简介：Renalcellcarcinoma(RCC)accountsforapproximately3%ofallcancercases.RCCsusuallymetastasizetothelungs,bones,liver,orbrain.Only<1%ofpatientswithbonemetastasesmanifestedclavicularRCCmetastases.Thus,clavicularmetastasisastheinitialpresentationofRCCisextremelyrare.WereportapatientwithRCCmetastasistotheleftclavicle,whichwasfirstpresentedwithpaincausedbyapathologicalfracture.Magneticresonanceimagerevealedarenaltumor,andtechnetium-99m–methylenediphosphonatebonescintigraphyshowedmultipleosseousmetastases.Thepatienteventuallyunderwentsurgerytoremovethelateralendoftheleftclavicleandrightkidney.Histopathologyrevealedrenaltumorandclearcellcarcinomaintheclavicle.Finally,wereview17casesofclavicularmetastasesoriginatingfromdifferentmalignancies.

简介：Objective:Tocomparetheefficacyandadverseeffectsofpaclitaxel-etoposide-carboplatin/cisplatin(TEP/TCE)regimenwiththoseofetoposide-carboplatin/cisplatin(EP/CE)regimenasfirst-linetreatmentforcombinedsmall-celllungcancer(CSCLC).Methods:Aretrospectivestudywasconductedon62CSCLCpatientswhoweretreatedatTianjinMedicalUniversityCancerInstituteandHospitalfromJuly2000toApril2013andadministeredwithTEP/TCEregimen(n=19)orEP/CEregimen(n=43)asfirst-lineCSCLCtreatment.Allpatientsreceivedmorethantwocyclesofchemotherapy,andtheresponsewasevaluatedeverytwocycles.Theprimaryendpointwasoverallsurvival(OS),andthesecondaryendpointswereprogression-freesurvival(PFS),objectiveresponserate(ORR),diseasecontrolrate(DCR),andadverseeffects.Results:ORRbetweentheTEP/TCEandEP/CEgroupsshowedastatisticaldifference(90%vs.53%,P=0.033).BothgroupsfailedtoreachastatisticaldifferenceinDCR(100%vs.86%,P=0.212).ThemedianPFSandOSoftheTEP/TCEgroupwereslightlylongerthanthoseoftheEP/CEgroup,althoughbothgroupsfailedtoreachastatisticaldifference(10.5vs.8.9months,P=0.484;24.0vs.17.5months,P=0.457).However,stratifiedanalysisindicatedthatthePFSofpatientswithstagesIIIandIVCSCLCshowedmarginallysignificantdifferencebetweentheTEP/TCEandEP/CEgroups(19.5vs.7.6months;P=0.071).BothratesofgradeIVbonemarrowdepressionandterminationofchemotherapyintheTEP/TCEgroupweresignificantlyhigherthanthoseintheEP/CEgroup(26.3%vs.7.0%,P=0.036;31.6%vs.14.7%,P=0.004).Conclusion:TheTEP/TCEregimenmaynotbepreferredforCSCLC,andthisthree-drugregimenrequiresfurtherexplorationandresearch.Todate,theEP/CEregimenremainsthestandardtreatmentforCSCLCpatients.